Anika Therapeutics reported $0 in Loan Capital for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Loan Capital Change
Acorda Therapeutics ACOR:US $ 184.98M 2.54M
Agios Pharmaceuticals AGIO:US $ 1.06M 0.78M
Arrowhead Research ARWR:US $ 0 0
Chemocentryx CCXI:US $ 4M 0.55M
Clovis Oncology CLVS:US $ 621.38M 7.38M
Enanta Pharmaceuticals ENTA:US $ 1.51M 0M
Halozyme Therapeutics HALO:US $ 1147.13M 359.03M
Insmed INSM:US $ 807.11M 447K
Integra Lifesciences IART:US $ 1.5B 3.89M
Karyopharm Therapeutics KPTI:US $ 302.69M 202K
Macrogenics MGNX:US $ 0 0
Merit Medical Systems MMSI:US $ 235.7M 7.41M
Peregrine Pharmaceuticals PPHM:US $ 141.8M 0.13M
Sangamo Biosciences SGMO:US $ 0M 0M
Stryker SYK:US $ 13374M 511M
Surmodics SRDX:US $ 0M 0M
Veracyte VCYT:US $ 0.6M 0M
Xencor XNCR:US $ 0M 0M
Zimmer Biomet Holdings Inc ZBH:US $ 5.17B 114.3M